Aminocaproic acid

What is this medication for?

• Degenerative myelopathy (GSD) — traditional (with NAC/vitamins); efficacy questionable (one study: no improvement, all progressed); investigational low platelet counts adjunct; human use: hyperfibrinolysis bleeding
• Antifibrinolytic: inhibits plasminogen activation → clot stability

How is it given?

Give exactly as your veterinarian prescribed — never change the dose or stop on your own unless your veterinarian has told you to.

• The DM mechanism story (plasmin-mediated spinal-cord damage) was always thin — an antifibrinolytic treating a neurodegenerative disease was the longest logical stretch in the pharmacy.
• The contraindication that matters pharmacologically: never where clots are the enemy (DIC, thrombosis).

What if I miss a dose?

• Give it as soon as you remember — unless it is almost time for the next dose (then skip the missed one; never double up).
• Call your clinic if you miss more than one dose in a row.

Side effects — what should I watch for?

Effects listed as common in this handout

• stomach/intestinal distress (Infrequent)
• Thrombosis risk (the mechanistic flip side) (Theoretical/real caution)

Worth a phone call to your veterinarian

• Any new symptom that worries you.

⚠️ Contact your veterinarian or an emergency clinic IMMEDIATELY if you notice

• Trouble breathing, collapse, seizures, severe vomiting or diarrhea, facial swelling, or pale gums

Before starting (or refilling), tell your veterinarian if your pet:

• has or has had: DIC (upper-urinary-tract bleeding with clot obstruction — human rule) — blocking fibrinolysis in active DIC = catastrophe
• has or has had: Any hypercoagulable state

• is pregnant, nursing, or used for breeding
• is taking any other medications, supplements, or flea/tick products, including:
  • Anticoagulants/antiplatelets
  • Factor concentrates

Storage and handling

Tablets/injection; expensive at dog doses (500 mg TID indefinitely).

Good to know

• Efficacy honesty: the classic GSD-DM "protocol drug" with weak evidence — one controlled-adjacent study showed zero benefit; modern view = supportive/exercise care, EACA optional tradition.
• The DM mechanism story (plasmin-mediated spinal-cord damage) was always thin — an antifibrinolytic treating a neurodegenerative disease was the longest logical stretch in the pharmacy.
• The contraindication that matters pharmacologically: never where clots are the enemy (DIC, thrombosis).